Figure 4
From: Development of a novel small antibody that retains specificity for tumor targeting
In vivo killing competency and the biodistribution of PMN. In vivo killing competency was compared with PBS, wt Ia, Fab-Ia and Sc-Ia in BALB/c athymic immunocomposed mice bearing MCF-7 tumors. (a) The tumors of mice were collected after 2-week administration. (b) The weights of each individual tumor were added together and the total weights were compared between groups. Compared with PBS, wt Ia, Fab-Ia and Sc-Ia, PMN could significantly suppress the growth of MCF-7 tumors (p < 0.05). PMN, protomimecin; wt Ia, wild-type colicin Ia; Fab-Ia, Fab segment from original antibody-colicin Ia fusion peptide; Sc-Ia, ScFv segment from original antibody-colicin Ia fusion peptide. (c) Fluorescence images of tumor (white arrow) in BALB/c mice traced by FITC-labeled PMN. The green fluorescence represented the location of FITC-labeled PMN protein. (d) Fluorescence images of incised tumor and vital organs from BALB/c mice traced by ip injecting FITC-labeled PMN. The green fluorescence showed the biodistribution of FITC-labeled PMN. T, tumor; S, spleen; L, liver; B, brain; M, muscle; K, kidney; I, intestine.